The NHS is rolling out a new drug intended to help people with multiple sclerosis improve their walking ability, in what has been described as a life-changing step for some patients. The treatment is notable because it is the first medicine specifically designed to target walking problems in people living with MS.
Multiple sclerosis is an incurable autoimmune disease that affects the brain and spinal cord. Because the condition disrupts signals in the nervous system, many patients develop mobility difficulties, including problems with balance, movement and walking.
The NHS rollout means eligible patients will be able to access a treatment focused on one of the most limiting symptoms of the disease. For people with MS, better walking ability can have a major effect on day-to-day independence, quality of life and routine activities.
The move also reflects a wider push to improve practical support for people managing long-term neurological conditions. While the drug is not a cure for multiple sclerosis, its availability through the NHS marks an important development for patients whose mobility has been affected by the disease.
